Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA.
Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
Blood Adv. 2022 Feb 22;6(4):1126-1136. doi: 10.1182/bloodadvances.2021005862.
For patients with blood cancers, comorbid mental health disorders at diagnosis likely affect the entire disease trajectory, as they can interfere with disease information processing, lead to poor coping, and even cause delays in care. We aimed to characterize the prevalence of depression and anxiety in patients with blood cancers. Using the Surveillance, Epidemiology, and End Results-Medicare database, we identified patients ≥67 years old diagnosed with lymphoma, myeloma, leukemia, or myelodysplastic syndromes between 2000 and 2015. We determined the prevalence of precancer depression and anxiety and cancer-associated (CA) depression and anxiety using claims data. We identified factors associated with CA-depression and CA-anxiety in multivariate analyses. Among 75 691 patients, 18.6% had at least 1 diagnosis of depression or anxiety. Of the total cohort, 13.7% had precancer depression and/or precancer anxiety, while 4.9% had CA-depression or CA-anxiety. Compared with patients without precancer anxiety, those with precancer anxiety were more likely to have subsequent claims for CA-depression (odds ratio [OR] 2.98; 95% CI 2.61-3.41). Other factors associated with a higher risk of CA- depression included female sex, nonmarried status, higher comorbidity, and myeloma diagnosis. Patients with precancer depression were significantly more likely to have subsequent claims for CA-anxiety compared with patients without precancer depression (OR 3.01; 95% CI 2.63-3.44). Female sex and myeloma diagnosis were also associated with CA-anxiety. In this large cohort of older patients with newly diagnosed blood cancers, almost 1 in 5 suffered from depression or anxiety, highlighting a critical need for systematic mental health screening and management for this population.
对于血液癌症患者,诊断时同时存在的精神健康障碍可能会影响整个疾病进程,因为它们会干扰疾病信息处理,导致应对能力差,甚至导致治疗延迟。我们旨在描述血液癌症患者中抑郁和焦虑的患病率。我们使用监测、流行病学和最终结果-医疗保险数据库,确定了 2000 年至 2015 年间被诊断患有淋巴瘤、骨髓瘤、白血病或骨髓增生异常综合征且年龄≥67 岁的患者。我们使用索赔数据确定了癌症前抑郁和焦虑以及与癌症相关的(CA)抑郁和焦虑的患病率。我们在多变量分析中确定了与 CA-抑郁和 CA-焦虑相关的因素。在 75691 名患者中,有 18.6%至少有 1 次抑郁或焦虑的诊断。在总队列中,有 13.7%的患者有癌症前抑郁和/或癌症前焦虑,而有 4.9%的患者有 CA-抑郁或 CA-焦虑。与没有癌症前焦虑的患者相比,有癌症前焦虑的患者更有可能随后被诊断出 CA-抑郁(比值比[OR]2.98;95%置信区间[CI]2.61-3.41)。与 CA-抑郁风险较高相关的其他因素包括女性、未婚、更高的合并症和骨髓瘤诊断。与没有癌症前抑郁的患者相比,有癌症前抑郁的患者更有可能随后被诊断出 CA-焦虑(OR 3.01;95%CI 2.63-3.44)。女性和骨髓瘤诊断也与 CA-焦虑相关。在这个新诊断为血液癌症的老年患者的大型队列中,近 1/5 的患者患有抑郁或焦虑,这突出表明该人群需要系统的心理健康筛查和管理。